Vall d'Hebron participates in a clinical trial to evaluate the efficacy and safety of low-dose selinexor in patients with severe COVID-19

The study will measure the time to clinical improvement of the patients, but will also include the mortality rate after 28 days, the percentage of patients who have required mechanical ventilation or ICU admission, among other parameters.

26/04/2020

Vall d'Hebron Barcelona Hospital Campus is leading a clinical trial promoted by Karyopharm Therapeutics that will study the effects of selinexor, a drug indicated to treat cancer, in patients with severe COVID-19. Vall d'Hebron is one of only two participating centers in Spain and we have already included the first patient. The other center is the Hospital de Salamanca and in the next few days new hospitals from around the world will be added.

Dr. Benito Almirante, head of the Infectious Diseases Service of the Vall d'Hebron Hospital and head of the research group on Infectious Diseases of the Vall d'Hebron Research Institute (VHIR) will be responsible for coordinating the clinical trial.

This is a randomized, single-blind, phase II trial that will assess the activity and safety of low-dose oral selinexor (KPT-330) in patients with severe COVID-19 infection. 230 patients will be recruited.

Patients who will undergo this treatment are in an urgent clinical situation after a diagnosis of COVID-19 confirmed by PCR and must be over 18 years of age.

The study will measure the time to clinical improvement evaluating clinical aspects such as the absence of fever for 24 hours without the need for antipyretics (paracetamol), an oxygen saturation greater than or equal to 94% without oxygen support, or a respiratory rate less than or equal to at 24 breaths per minute, among other parameters.

On the other hand, other aspects such as the mortality rate after 28 days, the percentage of patients who have required mechanical ventilation or admission to the ICU, the general evolution of patients according to age (older or younger than 70 years) will also be included.

In the same way, the anti-inflammatory and immune effects of selinexor will be analyzed, as well as its tolerability and safety at low doses to determine the capacity of this drug to modify the course of the disease.

Share it:

Related news

Related professionals

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.